Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ocuphire Pharma, Inc. (OCUP)
|
Add to portfolio |
|
|
|
| Price: |
$5.07
| | Metrics |
| OS: |
21.0
|
M
| |
|
|
| Market cap: |
$107
|
M
| |
|
|
|
Net cash:
|
$40
|
M
| |
$1.90
|
per share
|
|
EV:
|
$66.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | | | | | | |
| Research and development | 15.2 | 6.6 | 2.4 | 13.1 | 10.7 | 10.1 | 12.1 | 7.0 |
| General and administrative | 8.1 | 2.8 | 1.8 | 7.4 | 6.6 | 6.3 | 6.1 | 6.3 |
| EBIT | -22.7 | -9.5 | -4.2 | -20.5 | -17.4 | -16.4 | -18.3 | -13.3 |
| EBIT margin | -3854.8% | | | | | | | |
| Pre-tax income | -56.7 | -24.6 | -6.2 | -14.4 | -25.3 | -9.3 | -14.4 | -18.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -56.7 | -24.6 | -6.2 | -14.4 | -25.3 | -9.3 | -14.4 | -18.5 |
| Net margin | -9625.3% | | | | | | | |
| |
| Diluted EPS | ($3.82) | ($5.28) | ($2.17) | ($5.25) | ($0.92) | ($0.43) | ($0.79) | ($0.11) |
| Shares outstanding (diluted) | 14.9 | 4.7 | 2.8 | 2.7 | 27.4 | 21.7 | 18.2 | 176.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|